RecruitingOBSERVATIONAL

Clinical Pre-screening Protocol for Ovarian Cancer

This study aims to help doctors choose the most effective treatments for women with ovarian cancer. Researchers will examine a sample of your ovarian cancer tissue, taken during a previous procedure, using a special test called Drug Response Predictor® (DRP). This test is designed to predict which of Allarity Therapeutics’ experimental cancer drugs might work best for you if your disease progresses later on. The study will also look back at your previous treatments to see if the DRP® test could have predicted how well those drugs worked. This information helps doctors learn more about ovarian cancer and find better ways to treat it in the future, ultimately guiding treatment decisions.

At a glance

Status

Recruiting

Sponsor

Allarity Therapeutics

Enrolment target

Start

11 Apr 2019

Estimated completion

01 Dec 2026

Ovarian Cancer

What is this study about?

Ovarian cancer treatments can be really tough, and doctors are always looking for ways to make them more effective and personal. This study is designed to help do just that. Researchers want to understand if a special test, called Drug Response Predictor® (DRP), can effectively show which cancer medicines might work best for each individual with ovarian cancer. This means looking at your specific cancer to see what makes it unique.

To do this, the study will use a small piece of your ovarian cancer tissue, which was collected when you had surgery or a biopsy. This is often called 'archival tissue' because it's already stored safely. The DRP® test will then be performed on this tissue. The main goal is to see if this test can predict which of the *investigational* cancer drugs (medicines still being studied) from a company called Allarity Therapeutics might be most helpful for you down the line, if your cancer progresses again.

Beyond looking at future treatments, this study also aims to learn from the past. It will explore whether the DRP® test could have predicted how well previous chemotherapy drugs worked for your ovarian cancer. By understanding this, doctors can get a clearer picture of how effective the DRP® method is and how it might be used to guide treatment choices for other people with ovarian cancer in the future.

Key takeaways

Uses an existing ovarian cancer tissue sample (no new procedures).
Aims to predict which future drugs might work best for you.
Helps doctors understand how past treatments worked.
Applies to specific 'platinum-resistant' ovarian cancer.
Does not involve new treatments or medications; it's an analysis study.

Who may be eligible?

This study is for women who have been diagnosed with a specific type of ovarian cancer called epithelial ovarian cancer. To take part, your cancer must be considered 'platinum-resistant', which means it has grown or returned within six months after you finished a platinum-based chemotherapy. Alternatively, if platinum-based chemotherapy isn't suitable for you, you might also be eligible.

You should have had no more than one previous course of treatment for your platinum-resistant or platinum-ineligible ovarian cancer. Importantly, the doctors will need to be able to get a sample of your original ovarian cancer tissue, or tissue from a tumour that has spread, which was collected during a past procedure like a surgery or biopsy.

However, some people won't be able to join. For example, if your cancer got worse *during* your last platinum-based chemotherapy (this is called 'platinum-refractory'), you won't be eligible. Also, if you have another type of cancer, unless it's a very early stage cancer (stage 1 or 2) that your doctor believes has been cured, you won't be able to participate. Participants must also be 18 years old or older.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Have you been diagnosed with epithelial ovarian cancer?
Has your cancer returned or grown within 6 months of your last platinum chemotherapy?
Have you had 1 or fewer previous treatments for your platinum-resistant cancer?
Is there a past tissue sample from your ovarian cancer available?
Are you 18 years old or older?

Answer every question to see your result.

What does participation involve?

If you decide to participate in this study, the main part of it involves providing a small piece of your ovarian cancer tissue. This tissue would have been collected during a past surgery or biopsy and is already stored safely (it's called 'archival' tissue). You won't need to undergo any new procedures just for this study to get the tissue sample. Doctors will then use this sample to perform the special DRP® test.

There are no additional clinic visits, medications to take, or follow-up appointments directly related to this study. The study primarily involves the analysis of your existing tissue sample and medical records related to your past treatments. The total duration of your direct involvement is minimal, as it doesn't require active participation from you beyond the initial consent for your tissue to be used.

Potential risks and benefits

A potential benefit of taking part in this study is that the information gained from testing your tissue might help doctors understand which experimental drugs could be most effective for you in the future, if your ovarian cancer progresses. It will also contribute to our overall knowledge of ovarian cancer and how to treat it better for everyone. Since this study primarily uses an existing tissue sample and does not involve new procedures or medications, there are generally no physical risks to you. The main consideration is the use of your health information, which will be handled with strict privacy. You are always free to change your mind and withdraw from the study at any time, without it affecting your medical care.

Locations (5)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Dana-Farber Cancer Institute
Verified postcode
Boston, United States· Completed
OU Health Stephenson Cancer Center
Verified postcode
Oklahoma City, United States· Recruiting
Swedish Center for Research and Innovation
Verified postcode
Seattle, United States· Recruiting
Beatson West of Scotland Cancer Centre
Verified postcode
Glasgow, United Kingdom· Active not recruiting
Guy's and St Thomas' NHS Foundation Trust, Guy's Hospital
Verified postcode
London, United Kingdom· Active not recruiting

Common questions

What is 'platinum-resistant' ovarian cancer?

This means your ovarian cancer has grown or come back within six months after you completed your last treatment with a chemotherapy drug that contains platinum, like carboplatin or cisplatin.

What is the DRP® test?

The DRP® test is a special laboratory test that looks at your cancer tissue to try and predict which specific cancer drugs, particularly those being developed by Allarity Therapeutics, might work best for your unique cancer.

Will I get new treatment from this study?

No, this study does not provide new treatments or medications. It's focused on analysing your existing cancer tissue to gather information that could guide future treatment decisions.

Do I need to give a new tissue sample?

No, you don't need to provide a new tissue sample. The study uses a piece of your cancer tissue that was already collected during a previous surgery or biopsy and is stored by the hospital.

Will taking part affect my current treatment?

No, participating in this study will not affect any current or future medical care you receive for your ovarian cancer. It simply uses information from your past.

How to find out more

US: Kathleen Moore

kathleenmoore@ouhealth.com +1 405-271-8707 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.